In addition, high-dose chemotherapy followed by autologous stem cell transplant, or ASCT, continues to be the standard of care for multiple myeloma. Studies show that ASCT: Creates a deep and durable ...

Source Reference: Georges GE, et al "Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: Identifying disease risk factors for toxicity ...

A 59-year-old man is diagnosed with multiple myeloma. It is recommended that he receive induction therapy followed by high-dose melphalan with autologous hematopoietic stem-cell transplantation.

Stem cell transplants have three main phases: stem cell collection, pre-transplant treatment, and the transplant itself. The steps for autologous and allogenic transplants are very similar.

Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study. Authors: Peter Reimer, Thomas Rüdiger, Eva Geissinger, Florian ...

Hematopoietic stem cell transplantation is a treatment ... One 2017 study found that the median total healthcare cost at 100 days ranged from around $140,000 for an autologous HSCT to nearly $ ...

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the ...

Long-term disease-free survival (DFS) has been reported after autologous stem cell transplantation for acute lymphoblastic leukemia. Phase II studies have evaluated its role in first and ...

Despite roadblocks, "Autologous stem cell transplant is a truly life-saving intervention for patients who have juvenile onset systemic sclerosis," Torok says. "It is the best therapy for severe or ...

Drs Peter Martin and Brad Kahl discuss autologous stem cell transplantation for mantle cell lymphoma, the TRIANGLE trial results, and the transition toward use of Bruton tyrosine kinase inhibitors.

SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant of their stem cells, according to a new study.